Genentech's Polivy Combats DLBCL Effectively

Genentech has shared promising five-year follow-up data from the pivotal Phase III POLARIX study, which evaluated Polivy® (polatuzumab vedotin-piiq) in combination with R-CHP for previously untreated diffuse large B-cell lymphoma (DLBCL). Presented at the ASH Annual Meeting, the findings demonstrated a positive trend in overall survival (OS), with a reduction in the risk of death compared to the standard R-CHOP regimen. The safety profile remained consistent with no new concerns observed.

At five years, Polivy in combination with R-CHP showed maintained benefits in progression-free survival and disease-free survival, reinforcing its potential for long-lasting remission in DLBCL patients. Moreover, the study noted that patients treated with this combination required fewer follow-up interventions, such as chemotherapy or CAR-T cell therapy, compared to those on R-CHOP.

Currently approved in over 90 countries, Polivy with R-CHP is becoming a standard of care for DLBCL. Genentech is also exploring its use with other innovative therapies to further advance treatment options for this aggressive lymphoma.